cancer diagnostics News
-
Now recruiting: Bioinformatics Scientist
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
-
Amadix has developed a blood-based to detect colorectal cancer up to 15 years in advance
Rocío Arroyo, researcher, and CEO of Amadix, leads the team that has created an innovative blood-based test that can detect if a healthy person will develop a malignant colon tumour in the future. As an entrepreneur, Rocío turned her scientific knowledge into a viable business model securing private investors in Castile and Leon to found Amadix. Amadix is today a small ...
By Amadix
-
Former Roche Diagnostics NAM CEO Michael Tillmann joins X-ZELL executive board
X-ZELL is proud to announce the appointment of Michael Tillmann as member of the company’s executive board. Drawing on more than 30 years of experience in the pharmaceutical and diagnostics industry, Mr Tillmann previously held the CEO position at Roche Diagnostics North America and Asia Pacific. Between 2006 and 2010, he also served as a member of the company’s global executive ...
By X-Zell Inc.
-
The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology
Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing ...
-
The Centers for Medicare and Medicaid (CMS) announced the MCIT pathway to provide national Medicare coverage for FDA Breakthrough Devices and Diagnostic
The Centers for Medicaid and Medicare (CMS) announced the establishment of the MCIT (Medicare Coverage of Innovative Technology) pathway, which is designed to provide coverage and access to new, innovative medical devices and diagnostics which have received FDA Breakthrough Device Designation to Medicare beneficiaries nationwide. Through this pathway, Breakthrough devices will automatically be ...
-
Unbiased gene fusion analysis required in future cancer diagnostics
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
By Qlucore AB
-
Kheiron Medical Technologies Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
Kheiron Medical Technologies has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2022. Kheiron has pioneered the development and deployment of artificial intelligence solutions to help radiologists detect breast cancer earlier, and the company is currently leveraging its existing technologies and expertise to expand into new cancer ...
-
Dako, an Agilent Technologies Company, Announces Expanded Collaboration with Amgen Within Companion Diagnostics
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced a new Master Collaboration Agreement with Amgen Inc., a leading biotechnology company. The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products ...
-
Dako and Amgen Expand Collaboration with Plan to Develop New Diagnostic Test
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced a new project with Amgen to develop a molecular diagnostic test using Dako's IQFISH hybridization buffer. "We are pleased to continue our work with Amgen, particularly within the molecular arena," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics ...
-
Cleveland Diagnostics Announces FDA Breakthrough Device Designation for Novel Prostate Cancer Diagnostic Test
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received FDA Breakthrough Device Designation for the IsoPSA® Assay, a novel prostate cancer diagnostic test. Published studies from multicenter prospective clinical trials suggest that the non-invasive, blood-based IsoPSA ...
-
Stanford University Partners with Kheiron Medical Technologies to Pioneer Use of AI in New Areas of Oncology
Kheiron Medical Technologies today announced its new collaboration with researchers at Stanford University to design functional proof-of-concept deep learning models to solve clinical problems in novel ways, starting with Non-Hodgkin’s Lymphoma (NHL). With the collaboration, Kheiron, which has pioneered the development and deployment of artificial intelligence solutions to help radiologists ...
-
New Study Reinforces Major Advantages of Dako`s HER2 IQFISH pharmDx in Breast Cancer Diagnostics
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced positive findings in an independent French multicenter study on the performance of Dako's HER2 IQFISH pharmDx. The Toulouse, France, breast cancer group led by Magali Lacroix-Triki, has published a peer-reviewed publication in the Journal of Histopathology(1) that supports the use and performance ...
-
X-ZELL appoints Sebastian Grote as Managing Director
Singaporean medical technology specialist X-ZELL has appointed Sebastian Grote as Managing Director, effective from 1 March 2022. Grote previously served as Head of Marketing & Strategy at X-ZELL and has been with the company since 2017, when it first came out of stealth mode to raise a two-part, USD 5.6m seed round. Since then, he initiated a series of global brand-building campaigns that ...
By X-Zell Inc.
-
Cleveland Diagnostics Chief Medical Officer, Mark Stovsky, MD, Participates in Panel Discussion on Early Cancer Detection During Cleveland Clinic`s 2019 Medical Innovation Summit
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic. The Medical Innovation Summit, which is celebrating its 17th year, is covering a wide ...
-
Dako Collaborates on Review of Immunohistochemistry`s Impact on Prostate Diagnostics
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced the release of a new review paper titled "Immunohistochemistry in Prostate Pathology" that illustrates the significant impact immunohistochemistry (IHC) can have on diagnostic prostate pathology. The paper is co-authored by two leading global experts in prostate pathology: Glen Kristiansen, M.D., ...
-
Cleveland Diagnostics Receives College of American Pathologists (CAP) Accreditation for Its Clinical Laboratory
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its CLIA certified reference lab. The CAP Accreditation is awarded to laboratories that meet stringent requirements and maintain the ...
-
FDA Approves Seno Medical’s Ground-Breaking Breast Cancer Diagnostic Technology
The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions. The company’s Imagio® Breast Imaging System ...
-
Dako, an Agilent Technologies Company, Launches Two Ready-to-Use Antibodies for Cancer Diagnosis
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostic solutions, today announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to the Dako portfolio of high-quality reagents, instruments and software. Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. It is used by ...
-
Dako Publishes Sixth Edition of Immunohistochemistry Guidebook
Dako, an Agilent Technologies Company and worldwide provider of cancer diagnostics, today introduced the latest version of "The Educational Guidebook: IHC Staining Methods." Since Dako released the guidebook's fifth edition in 2009, more than 20,000 copies have been published, plus an additional 3,000 online copies downloaded each year. This globally recognized book on IHC staining methods is ...
-
Publication of a Health Economic Analysis Demonstrates IsoPSA Significantly Reduces Unnecessary Prostate Cancer Biopsies and Costs
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company focused on the development of next-generation diagnostic tests for early detection of cancers, announced today the publication of a health economic analysis in Urology Practice. The publication demonstrates the cost effectiveness and economic utility of Cleveland Diagnostics’ IsoPSA test for the detection of clinically ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you